sprite-preloader
Freitag, 25.04.2014 Börsentäglich über 12.000 News von 475 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1J84E ISIN: US00287Y1091 Ticker-Symbol: 4AB 
Aktie:
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
ABBVIE INC Chart 1 Jahr
1-Woche-Intraday-Chart
ABBVIE INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
35,64
35,78
24.04.
35,61
35,75
24.04.

Aktuelle News zu ABBVIE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
ABBVIE Aktie jetzt ab 5 Dollar handeln!

--> Artikel lesen
01:40Will AbbVie (ABBV) Disappoint This Earnings Season? - Analyst Blog-

--> Artikel lesen
DoWill AbbVie (ABBV) Disappoint This Earnings Season?2

--> Artikel lesen
DoQuarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie13
NEW YORK, April 24, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries...
--> Artikel lesen
MiAbbVie Files for HCV Combination Therapy in U.S.1

--> Artikel lesen
MiAbbvie submits NDA to FDA for hepatitis C drug-

--> Artikel lesen
MiAbbVie to Present Data on Investigational Compounds at the 2014 American Society of Clinical Oncology Annual Meeting3
NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ --AbbVie (NYSE: ABBV) today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented...
--> Artikel lesen
MiBRIEF-Ablynx initiates phase I study of anti-il-6R nanobody with Abbvie2

--> Artikel lesen
MiAblynx: ABLYNX INITIATES PHASE I BIOAVAILABILITY STUDY WITH SUBCUTANEOUS FORMULATION OF ITS ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE4
GHENT, Belgium, 23 April 2014 - Ablynx [Euronext Brussels: ABLX] today announced that it has started dose administration in healthy volunteers in a Phase I clinical trial as part of the evaluation...
--> Artikel lesen
DiEnanta gets first half of $40M milestone payment from AbbVie3

--> Artikel lesen
DiAbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck22

--> Artikel lesen
DiAbbVie, Inc. Reports Submission of GT1/HCV Treatment NDA to FDA2

--> Artikel lesen
DiAbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C4
NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ --AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational...
--> Artikel lesen
18.04.AbbVie urges U.S. court to avoid gay rights issue in HIV drug case3

--> Artikel lesen
17.04.Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead56

--> Artikel lesen
17.04.AbbVie Candidate in Pivotal Study6

--> Artikel lesen
17.04.The Zacks Analyst Blog Highlights:GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics39
CHICAGO, April 17, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
--> Artikel lesen
16.04.Application Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship7
NORTH CHICAGO, Ill., April 16, 2014 /PRNewswire/ --AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship...
--> Artikel lesen
15.04.AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer7
NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ --AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound...
--> Artikel lesen
15.04.AbbVie PT Raised to $61.00 at Jefferies Group6

--> Artikel lesen
14.04.Positive Data on AbbVie's HCV Program - Analyst Blog5

--> Artikel lesen
Seite:  Weiter >>
236 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
ABBVIE INC-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten
GILEAD SCIENCES52,94-2,29 %Gilead Sciences-Aktie: Quartalszahlen dank Solvadi au
San Francisco - Gilead Sciences-Aktienanalyse von Analyst Brian Abrahams von Wells Fargo Advisors: Der Aktienanalyst Brian Abrahams von Wells Fargo Advisors stuft die Aktien des US-Biotechkonzerns Gilead...
--> Artikel lesen
ABBOTT LABORATORIES27,925-0,55 %Equities to Watch in the Health Care Sector -- Research on Boston Scientific, Abbott Laboratories, Medtronic, and Insulet
LONDON, April 24, 2014 /PRNewswire/ -- The trading session on Wednesday, April 23, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,501.65, down 0.08% and the NASDAQ...
--> Artikel lesen
NOVO NORDISK32,13-0,70 %NASDAQ OMX Copenhagen A/S: Novo Nordisk A/S - reduction in share capital by the cancellation of treasury shares
The share capital of the following share will be reduced in NASDAQ OMX systems as per 25 April 2014 due to the cancellation of treasury shares. ISIN: DK0060534915 ...
--> Artikel lesen
NOVARTIS61,20-2,13 %dpa-AFX Überblick: ANALYSTEN-EINSTUFUNGEN vom 22.04.2014: ADIDAS, AIRBUS, ASTRAZENECA, AXEL SPRINGER, BARCLAYS, BASF, BAYER, BB BIOTECH, BRENNTAG, CONTINENTAL, CREDIT SUISSE, DAIMLER, DEUTSCHE BANK, DIAGEO, ...
Ausgewählte Analysten-Einstufungen im dpa-AFX-Nachrichtendienst vom 22.04.2014 ADIDAS NEW YORK - Die US-Bank JPMorgan hat die Einstufung für Adidas vor Zahlen auf "Overweight" mit einem Kursziel...
--> Artikel lesen
CELGENE101,18-4,55 %Celgene Q1 Adj. Profit Tops View, Backs 2014 View
SUMMIT (dpa-AFX) - Drug maker Celgene Corp. (CELG) reported first-quarter net income of $279.7 million or $0.66 per share, down from $384.9 million or $0.89 per share in the prior-year quarter.Adjusted...
--> Artikel lesen
Lade...